1 June 2015
Silence Therapeutics plc
Result of General Meeting
Silence Therapeutics plc, AIM: SLN, ("Silence" or "the Company"), a leader in the development and delivery of novel RNA therapeutics, announces that at its Annual General Meeting held earlier today, all resolutions were duly passed.
Enquiries:
Silence Therapeutics plc |
+44 (0)20 3700 9711 |
Timothy Freeborn, Finance Director & Company Secretary |
|
Rozi Morris, Communications Manager |
|
|
|
Canaccord Genuity Limited (Nominated Adviser and Joint Broker) |
+44 (0)20 7523 8350 |
Dr Julian Feneley/Peter Stewart/Cara Griffiths |
|
Peel Hunt LLP (Joint Broker) |
+44 (0)20 7418 8900 |
James Steel/ Oliver Jackson |
|
About Silence Therapeutics (www.silence-therapeutics.com)
Silence Therapeutics is a leading RNA therapeutics company. It has developed proprietary modifications to improve the robustness of RNA sequences together with advanced liposomal chemistries to enhance the delivery of its therapeutics. Its technology can selectively silence or replace the expression of any gene in the genome, modulating expression up as well as down in a variety of organs and cell types, in vivo. This allows the development of therapeutics for diseases with high unmet clinical need.